🔎 Search anything on the website

PointCross Blog

Mitigating risk with PointCross 

As some may have heard, the FDA released their bi-annual update to the Technical Conformance Guide earlier this year. Along with slight corrections and improvements, an entire Appendix was added regarding SEND data review "Best Practices". With the update, the FDA has formalized some industry wide best practices; better quality SEND datasets equates to...

5 SEND Compliance Challenges Nonclinical CROs Must Solve

This article breaks down the real SEND compliance challenges that nonclinical CROs face, grounded in current FDA and CDISC requirements, and shows where disciplined process and the right tooling change the outcome. We write this for toxicologists, regulatory affairs professionals, bioinformaticians, pharma and biotech executives, and the IT and data teams who live with...

What the FDA’s TCG v6.2 Update Means for Your SEND Deliverables

The FDA has rolled out version 6.2 of its Study Data Technical Conformance Guide, and if you sponsor nonclinical studies, it is worth understanding what changed before your next submission lands. Most of the update simply codifies practices that experienced SEND providers already follow - but there is one structural change that will affect...

Welcoming PingPing Gong to PointCross

As part of our continued global expansion, PointCross Life Sciences is pleased to welcome PingPing Gong as Senior Director, Business Development – China / APAC. Based in Shanghai, Pingping will lead business development initiatives across China and the broader APAC region. She brings extensive experience partnering with CROs and sponsors, supporting the adoption of scalable...

Three Steps to Transforming CRO Productivity: Time, Cost, and Quality in Nonclinical Study Reporting

Nonclinical contract research organizations (CROs) face a structural inefficiency in the preparation of exploratory and pivotal toxicology study packages: the Study Report and its companion SEND (Standard for Exchange of Nonclinical Data) dataset are generated through two separate, sequential processes from the same underlying data. This sequential workflow adds 4-5 weeks to submission timelines,...

PointCross at PHUSE US Connect 2026

At PHUSE US Connect 2026 in Austin, PointCross Life Sciences’ Rahul Madhavan, alongside collaborators from Merck Group and Daiichi Sankyo, led a hosted session on “Building a Better MDR” and introduced the soft launch of an industry-first white paper. What began as an observational critique of spreadsheet-based standards management evolved into a broader vision -...

SOT 65th Annual Meeting and ToxExpo

Date: March 22–26, 2026Location: San Diego, California PointCross attended the Society of Toxicology (SOT) 65th Annual Meeting and ToxExpo, held March 22–26, 2026, in San Diego, CA. The event brought together leading toxicologists, researchers, regulators, and industry professionals to share the latest scientific discoveries, technologies, and regulatory advancements in toxicology. At Booth #2107, the PointCross team...

PointCross at Phuse APAC Connect 2026

PointCross Life Sciences was proud to participate in PHUSE APAC Connect 2026, held from 19–21 February 2026 in Hyderabad, India. The event brought together global leaders across clinical data science, innovation, and regulatory standards, alongside India CDISC Day, uniting two influential data standards communities under one platform. During the conference, PointCross contributed through both paper and...

Revolutionary Single – Track Process Transforms Nonclinical Data Management

Xbiom™ Platform Introduces AI-Enabled Automated Workflow that Eliminates Redundant Processes, Reduces Costs by 50%, and Accelerates IND-Enabling Regulatory Submission Readiness by 2-4 Weeks. Foster City, CA, December 18, 2025 PointCross today announced general availability of an AI augmented transformative single-track process for nonclinical data management. The innovation enables simultaneous generation of submission-ready Study Reports and...

Does my Study need SEND?

As a toxicologist running multiple GLP and non-GLP studies, you and your team often plan budgets, study schedules, and contracting activities with your CRO and external vendor labs.  There is, often times, one critical-path topic that often appears as a line item in a Statement of Work between you and your CRO partner. That line...

PHUSE EU Connect 2025

Event Date: 16 – 19 November 2025Location: Hamburg, Germany 𝐀𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐚𝐭𝐚 𝐠𝐫𝐨𝐰𝐬 𝐦𝐨𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱, 𝐦𝐞𝐭𝐚𝐝𝐚𝐭𝐚 𝐜𝐚𝐧’𝐭 𝐛𝐞 𝐚𝐧 𝐚𝐟𝐭𝐞𝐫𝐭𝐡𝐨𝐮𝐠𝐡𝐭.At PHUSE EU Connect 2025, Harinarayan Gopichandran, VP Technical Solutions at PointCross, demonstrated how the 𝐗𝐛𝐢𝐨𝐦 𝐒𝐦𝐚𝐫𝐭 𝐌𝐞𝐭𝐚𝐝𝐚𝐭𝐚 𝐑𝐞𝐩𝐨𝐬𝐢𝐭𝐨𝐫𝐲 (𝐌𝐃𝐑) helps Sponsors and CROs 𝘴𝘵𝘳𝘦𝘢𝘮𝘭𝘪𝘯𝘦 clinical trial setup, 𝘢𝘶𝘵𝘰𝘮𝘢𝘵𝘦 metadata governance, and 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 consistency across studies. Managing metadata through...

Refreshing Clinical Data Validation for Modern BioPharma

Validation and study data quality should be thought of as iterative and continuous workflows. Yet, many teams still work within usage models and contract terms that make it harder to validate for rules and conformance checks as often as needed. eDataValidator was designed to change that. Built by PointCross, and used for well over 100,000...

PointCross at PHUSE SDE Bengaluru 2025 – Gold Sponsor

Event Date: Saturday, 22 November 2025Location: Bengaluru, India About the Event The PHUSE Single Day Event (SDE) in Bengaluru brought together leaders across the clinical research ecosystem to discuss how emerging technologies -AI, ML, RPA, and intelligent data systems are transforming clinical data science. With the industry rapidly shifting toward automation and real-time analytics, the event...

Metadata Repository: Your Strategic Edge in Clinical Development

Most research organizations spend 16-20 weeks setting up each clinical trial. Six of those weeks go to creating SDTM datasets alone. This isn't just slow. It's expensive, risky, and getting worse as regulatory requirements grow more complex. The problem isn't the work itself. It's how we manage the metadata that gives meaning to clinical data What...

Bridging the Gap: How Natural Language AI Can Transform Clinical Data Access

As the BioPharma industry evolves toward more data-intensive, portfolio-wide agile decision-making, under pressure to innovate and reduce the time to market, organizations that master bridging the questions of their staff to regulatory compliant, verifiable responses retrieved from their study data systems will move faster, decide smarter, and ultimately bring therapies to patients more efficiently,...